# Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

Source: https://onco.cc/trials/nct03603795/  
OnCo record `nct03603795` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Eltrombopag in Acute myeloid leukaemia, run by French Innovative Leukemia Organisation, active and no longer recruiting.

## Summary

Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy is a phase 2 interventional study registered as NCT03603795 by French Innovative Leukemia Organisation, with 110 participants planned, started 2018-10-11 and due to reach its primary completion in 2022-06-15. Interventions recorded: Eltrombopag, Placebo. Conditions recorded: Acute Myeloid Leukemia.

Linked to the drug Eltrombopag because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03603795
- Phase: 2
- Setting: A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy
- Sponsor: French Innovative Leukemia Organisation
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT03603795: https://clinicaltrials.gov/study/NCT03603795

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Eltrombopag](https://onco.cc/drugs/eltrombopag/)

---
JSON: https://onco.cc/api/v1/entities/nct03603795.json